 Amneal Pharmaceuticals Inc NYSE: AMRX announced topline data from the Phase 3 RISE-PD trial evaluating IPX-203 in patients with Parkinsons disease who have motor fluctuations. Amneal plans to submit a marketing application for IPX-203 with the FDA in mid-2022. 